Medical Isotope Production Market Growth

Global Medical Isotope Production Market Growth is Anticipated at CAGR of 8.3%; Market Value to Grow to USD 15.06 Billion by 2040 | Roots Analysis

According to a recently published report by Roots Analysis, the rising prevalence of chronic diseases coupled with the ongoing advancements in the nuclear imaging technology is driving the medical isotope production market growth.

Global Medical Isotope Production Industry Overview

The global medical isotope production market is expected to reach around USD 15.06 billion by 2040, growing at a CAGR of 8.3% during the forecast period till 2040.

Given the rising geriatric population along with the increasing prevalence of chronic diseases and surge in imaging procedures using radionuclides, the demand for novel medical isotopes has grown significantly. Moreover, several challenges associated with conventional diagnostic and therapeutic techniques, such as procedural complexities, lengthy processing time and lower success rates have prompted a shift towards more advanced solutions in modern medicine like medical isotopes.

In fact, due to their high target specificity and strong therapeutic efficacy, medical isotopes have revolutionized the diagnosis and treatment of several chronic diseases (especially cancer). Notably, over 50 million medical procedures utilizing isotopes are performed globally each year, offering critical insights into organ function and disease progression.  

Further, due to technological advancements in isotope production technology, coupled with AI-powered algorithms, medical isotopes present a transformative opportunity, to enhance efficiency and accuracy across various healthcare applications.

Browse 150+ figures and ~160 market data tables spread across ~360 slides and detailed Table of Content on “Global Medical Isotope Production Market, till 2040 by Scale of Operation (Commercial Scale and Preclinical / Clinical Scale), Type of Isotope (Radioisotopes and Stable Isotopes), Radioisotope (Technetium-99m, Fluorine-18, Leutetium-177, Actinium-225 and Other Radioisotopes), Production Method (Nuclear Reactors, Accelerators and Other Methods), Application Area (Diagnosis, Nuclear Therapy and Other Applications), Type of Diagnostic Radioisotope (SPECT Radioisotopes and PET Radioisotopes), Type of Therapeutic Radioisotope (Beta Emitters, Alpha Emitters and Other Emitters), Therapeutic Area (Oncological Disorders, Cardiovascular Disorders, Neurological Disorders and Other Disorders), End Users (Hospitals, Diagnostic Centers and Research Institutes), Geographical Regions (North America (US and Canada), Europe (Germany, Netherlands, UK, Belgium, France, Russia and Rest of Europe), Asia-Pacific (Australia, China, India, Japan and Rest of Asia-Pacific), Middle East and Africa (South Africa, Israel and Rest of Middle East and Africa), and Latin America (Argentina and Rest of Latin America)), and Leading Players: https://www.rootsanalysis.com/reports/medical-isotope-production-market.html

Market Drivers

Several factors are propelling the global medical isotope production market growth. One of the key factors driving the future of the medical isotope production market is the rising prevalence of cancer. According to the World Health Organization, by 2050, new cancer cases are expected to exceed 35 million, representing approximately 80% increase from the number of cases reported in 2022.

This has intensified the demand for medical isotopes to deliver rapid and precise imaging results and effectively manage such conditions. It is imperative to state that owing to such escalated levels of cancer cases, along with innovations in production technologies (such as cyclotron-based production methods), the medical isotope production market is anticipated to witness substantial growth in the foreseen future.

Market Restraints

While the global medical isotope production market is experiencing substantial growth, there are certain restraints that can hinder the growth of the industry. One of the primary challenges is navigating the regulatory complexities associated with the licensing of radioisotope production facilities. In fact, stringent requirements are mandated by regulatory bodies, such as the Nuclear Regulatory Commission (NRC) and Atomic Energy Regulatory Board (AERB) for safety compliance.

In addition to this, facilities must implement robust physical protection and security measures to prevent unauthorized access or misuse of radioactive materials. Moreover, navigating this process involves extensive documentation, making it both demanding and time-consuming. Additionally, logistical challenges associated with the short half-life of many medical isotopes have been a major obstacle for the broader adoption of medical isotopes.

Growth Factors

Despite the aforementioned restraints, several growth factors continue to drive the global medical isotope production market forward. One notable factor is the increased funding initiatives for nuclear medical research, creating substantial opportunities for advancing diagnostic and therapeutic technologies to treat various chronic conditions. Further, governments are providing financial support to encourage large scale production of medical isotopes. For instance, in 2024, the Dutch government allocated funds worth EUR 10.5 million to enhance the production of medical isotopes, such as Terbium-161 for the treatment of cancer.

In addition to this, the expanding applications of medical isotopes in personalized therapy creates opportunities to provide targeted radionuclide therapies based on individual patient profiles which significantly improve the overall therapeutic outcomes. Owing to the aforementioned factors, it can be anticipated that the global medical isotope production market will flourish remarkably in the foreseen future.

Global Medical Isotope Production Market Segments

Based on the scale of operation, the market is segmented into commercial scale and preclinical / clinical Scale.

• The commercial scale segment led the global medical isotope production market, capturing the largest revenue share of around 90% in the current year.
• The preclinical / clinical scale segment is anticipated to grow at a higher CAGR of 9.21%, during the forecast period.

Based on the type of isotope, the market is segmented into radioisotopes and stable isotopes.

• The radioisotopes segment led the global medical isotope production market, capturing the largest revenue share of over 85% in the current year.
• In fact, the radioisotopes segment is anticipated to grow at a higher CAGR of 8.42%, during the forecast period.

Based on the radioisotopes, the market is segmented into Technetium-99m, Fluorine-18, Leutetium-177, Actinium-225 and other radioisotopes.

• The Technetium-99m radioisotope segment led the global medical isotope production market, capturing the largest revenue share of around 80% in the current year.
• The Leutetium-177 radioisotope segment is anticipated to grow at a higher CAGR of 10.69% during the forecast period.

Based on the production method, the market is segmented into nuclear reactors, accelerators and other methods.

• The nuclear reactors segment led the global medical isotope production market, capturing the largest revenue share of approximately 75% in the current year.
• The accelerators segment is anticipated to grow at a higher CAGR of 11.70% during the forecast period.

Based on the application area, the market is segmented into diagnosis, nuclear therapy and other applications.

• The diagnosis segment led the global medical isotope production market, capturing the largest revenue share of more than 85% in the current year.
• The nuclear therapy segment is anticipated to grow at a higher CAGR of 11.00% during the forecast period.

Based on the type of diagnostic radioisotope, the market is segmented into SPECT radioisotopes and PET radioisotopes.

• The SPECT radioisotopes segment led the global medical isotope production market, capturing the largest revenue share of around 80% in the current year.
• The PET radioisotopes segment is anticipated to grow at a higher CAGR of 8.86% during the forecast period.

Based on the type of therapeutic radioisotope, the market is segmented into beta emitters, alpha emitters and other emitters.

• The beta emitters segment led the global medical isotope production market, capturing the largest revenue share of around 65% in the current year.
• The alpha emitters segment is anticipated to grow at a higher CAGR of 13.12% during the forecast period.

Based on the therapeutic area, the market is segmented into oncological disorders, cardiovascular disorders, neurological disorders and other disorders.

• The oncological disorders segment led the global medical isotope production market, capturing the largest revenue share of almost 40% in the current year.
• The neurological disorders segment is anticipated to grow at a higher CAGR of 11.54% during the forecast period.

Based on end users, the market is segmented into hospitals, diagnostic centers and research institutes.

• The hospitals segment led the global medical isotope production market, capturing the largest revenue share of around 50% in the current year.
• The research institutes’ segment is anticipated to grow at a higher CAGR of 9.15% during the forecast period.

Based on the regional insights, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America.

• North America dominated the global medical isotope production market and accounted for the largest revenue share of more than 40% in the current year.
• In Asia-Pacific, the global medical isotope production market is anticipated to demonstrate lucrative growth during the forecast period.

Key Companies Profiled

The global medical isotope production market report also includes detailed profiles of key manufacturers (listed below) that are engaged in manufacturing medical isotopes:

• Actinium Pharmaceuticals
• Bayer
• Fussion Pharmaceuticals
• IRE
• Jubilant Radiopharma
• Kinectrics
• Lantheus
• Novartis
• NTP Radioisotopes
• Siemens Healthineers
• Taiyo Nippon Sanso  
• Telix

You Can Download Free Sample PDF Copy Of This Report At:

https://www.rootsanalysis.com/reports/medical-isotope-production-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary

Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com